Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
BMY Neutral Sentiment
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
Key Takeaway: Bristol Myers Squibb has released its financial results for the second quarter of 2026. The report highlights the company's performance metrics and financial health during this period. Further details on revenue, expenses, and other financial indicators were provided, reflecting the company's current standing in the biopharma market.
Price reaction · baseline $63.1 (2026-07-29 close) · hit pre-market · clean, no other BMY news in the window
day 0 close · peak
+2.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Pneumococcal polysaccharide vaccine
Phase 3 · Multiple Sclerosis